Research has also shown that targeting exosomes from DHODH and GPX4 enhances sorafenib-induced ferritic anaemia, thereby increasing the sensitivity of hepatocellular carcinoma (HCC) cells to sorafenib (Li et al. 2022a). This evidence concerns the gene GPX4 and hepatocellular carcinoma.